安罗替尼在非小细胞肺癌的治疗进展及不良反应管理
Advances in the Treatment of Non-Small Cell Lung Cancer with Anlotinib and Adverse Re-action Management
DOI: 10.12677/ACM.2022.12121706, PDF,   
作者: 卢 鑫：青海大学研究生院，青海 西宁；姜 军*：青海大学附属医院肿瘤内科三病区，青海 西宁
关键词: 安罗替尼；肿瘤；不良反应；Anlotinib； Tumor； Adverse Reactions
摘要: 肺癌是全球发病率、死亡率最高的恶性肿瘤，严重危害人类的健康。肺癌分为小细胞肺癌和非小细胞肺癌，其中后者占肺癌的80%~85%。近年来随着靶向治疗的兴起，使非小细胞肺癌的治疗取得了巨大进展，安罗替尼是一种新型的小分子多靶点酪氨酸激酶抑制剂，通过抗血管生成作用抑制肿瘤的生长及转移，具有多靶点、安全性好等优点，在多种恶性肿瘤中被广泛研究。本文就安罗替尼在非小细胞肺癌的治疗进展及不良反应的管理进行综述。
Abstract: Lung cancer is a malignant tumor with the highest morbidity and mortality in the world, which se-riously endangers human health. Lung cancer is divided into small cell lung cancer and non-small cell lung cancer, the latter of which accounts for 80%~85% of lung cancer. In recent years, with the rise of targeted therapy, great progress has been made in the treatment of non-small cell lung can-cer. Anlotinib is a novel small molecule multitarget tyrosine kinase inhibitor, which can inhibit tu-mor growth and metastasis through anti-angiogenesis effect. It has the advantages of multi-target and good safety, and has been widely studied in a variety of malignant tumors. This article reviews the progress of antirotinib in the treatment of non-small cell lung cancer and the management of adverse reactions.
文章引用：卢鑫, 姜军. 安罗替尼在非小细胞肺癌的治疗进展及不良反应管理[J]. 临床医学进展, 2022, 12(12): 11844-11851. https://doi.org/10.12677/ACM.2022.12121706

参考文献

[1] Jemal, A., Thomas, A., Murray, T., et al. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 52, 23-47. [Google Scholar] [CrossRef] [PubMed]
[2] Zhi, X.Y., Zou, X.N., Hu, M., et al. (2015) Increased Lung Cancer Mortality Rates in the Chinese Population from 1973-1975 to 2004-2005: An Adverse Health Effect from Exposure to Smoking. Cancer, 121, 3107-3112. [Google Scholar] [CrossRef] [PubMed]
[3] Bl, A., Xs, B., Dy, A., et al. (2018) Anlotinib Inhibits Angiogenesis via Suppressing the Activation of VEGFR2, PDGFRβ and FGFR1. Gene, 654, 77-86. [Google Scholar] [CrossRef] [PubMed]
[4] Shen, G., Zheng, F., Ren, D., et al. (2018) Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development. Journal of Hematology & Oncology, 11, Article No. 120. [Google Scholar] [CrossRef] [PubMed]
[5] Han, B., Li, K., Wang, Q., et al. (2018) Effect of Anlotinib as a Third-Line Orfurther Treatment on Overall Survival of Patients with Advanced Nonsmall Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncology, 4, 1569-1575. [Google Scholar] [CrossRef] [PubMed]
[6] Cheng, Y., Wang, Q., Li, K., et al. (2021) Anlotinib vs Placebo as Third- or Further-Line Treatment for Patients with Small Cell Lung Cancer: A Randomised, Double-Blind, Place-bo-Controlled Phase 2 Study. British Journal of Cancer, 125, 366-371. [Google Scholar] [CrossRef] [PubMed]
[7] Li, D., Chi, Y., Chen, X., et al. (2021) Anlotinib in Locally Ad-vanced or Meta-Static Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase ⅡB Trial. Clinical Cancer Research, 27, 3567-3575. [Google Scholar] [CrossRef] 
[8] Chi, Y., Fang, Z., Hong, X., et al. (2018) Safety and Effi-cacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research, 24, 5233-5238. [Google Scholar] [CrossRef] 
[9] Sun, Y., Zhou, A., Zhang, W., et al. (2021) Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma: An Open-Label Phase II Study (ALTER-0802 Study). Hepatology International, 15, 621-629. [Google Scholar] [CrossRef] [PubMed]
[10] Ma, J., Song, Y., Shou, J., et al. (2020) Anlotinib for Patients with Metastatic Renal Cell Carcinoma Previously Treated with One Vascular Endothelial Growth Factor Recep-tor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. Frontiers in Oncology, 10, 664. [Google Scholar] [CrossRef] [PubMed]
[11] Huang, J., Xiao, J., Fang, W., et al. (2021) Anlotinib for Previously Treated Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Double-Blind Randomized Phase 2 Trial. Cancer Medicine, 10, 1681-1689. [Google Scholar] [CrossRef] [PubMed]
[12] Chi, Y., Shu, Y., Ba, Y., et al. (2021) Anlotinib Monotherapy for Refrac-tory Metastatic Colorectal Cancer: A Double-Blinded, Placebo Controlled, Randomized Phase III Trial (ALTER0703). The Oncologist, 26, e1693-e1703. [Google Scholar] [CrossRef] [PubMed]
[13] Majidpoor, J. and Mortezaee, K. (2021) Angiogenesis as a Hallmark of Solid Tumors. Clinical Perspectives Cellular Oncology, 44, 715-737. [Google Scholar] [CrossRef] [PubMed]
[14] Folkman, J. (1995) Angiogenesis in Cancer, Vascular, Rheuma-toid and Other Disease. Nature Medicine, 1, 27-31. [Google Scholar] [CrossRef] [PubMed]
[15] Nishida, N., Yano, H., Nishida, T., Kamura, T. and Kojiro, M. (2006) An-giogenesis in Cancer. Vascular Health and Risk Management, 2, 213-219. [Google Scholar] [CrossRef] [PubMed]
[16] Cardoso, H.J., Figueira, M.I., Correia, S., et al. (2014) The SCF/c-KIT System in the Male: Survival Strategies in Fertility and Cancer. Molecular Reproduction and Development, 81, 1064-1079. [Google Scholar] [CrossRef] [PubMed]
[17] Han, B., Li, K., Zhao, Y., et al. (2018) Anlotinib as a Third-Line Therapy in Patients with Refractory Advanced Non-Small-Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (ALTER0302). British Journal of Cancer, 118, 654-661. [Google Scholar] [CrossRef] [PubMed]
[18] Cheng, Y., Han, B., Li, K., et al. (2020) Effect of Anlotinib as a Third or Further-Line Therapy in Advanced Non-Small Cell Lung Cancer Patients with Different Histologic Types: Subgroup Analysis in the ALTER0303 Trial. Cancer Medicine, 9, 2621-2630. [Google Scholar] [CrossRef] [PubMed]
[19] Liang, W., Zhao, Y., Zhang, Y., et al. (2018) The Impact of Anlotinib on Brain Metastases of NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303). Journal of Thoracic Oncology, 13, S665. [Google Scholar] [CrossRef] 
[20] Chu, T., Zhang, W., Zhang, B., et al. (2022) Efficacy and Safety of First-Line Anlotinib-Based Combinations for Advanced Non-Small Cell Lung Cancer: A Three-Armed Prospective Study. Translational Lung Cancer Research, 11, 1394. [Google Scholar] [CrossRef] [PubMed]
[21] Yang, X., et al. (2019) Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Pro-tocol for Phase II Clinical Trial. Asian Pacific Journal of Cancer Prevention: APJCP, 20, 3849-3853. [Google Scholar] [CrossRef] 
[22] Huang, D., Zhong, D., Zhang, C., et al. (2020) Study of Anlotinib Combined with Icotinib as the First-Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients Har-boring Activating EGFR Mutations (ALTER-L004). Journal of Clinical Oncology, 38, 9573. [Google Scholar] [CrossRef] 
[23] Shi, Y., Ji, M., Jiang, Y., et al. (2022) A Cohort Study of the Efficacy and Safety of Immune Checkpoint Inhibitors plus Anlotinib versus Immune Checkpoint Inhibitors Alone as the Treatment of Advanced Non-Small Cell Lung Cancer in the Real World. Translational Lung Cancer Research, 11, 1051-1068. [Google Scholar] [CrossRef] [PubMed]
[24] Xiang, Y., Lu, X.J., Sun, Y.H., et al. (2022) Precise Thera-peutic Benefits and Underlying Mechanisms of Anlotinib Combined with Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer. World Journal of Oncology, 13, 320-324. [Google Scholar] [CrossRef] [PubMed]
[25] Sun, Y., Niu, W., Du, F., et al. (2016) Safety, Pharmacokinetics, and An-titumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients with Advanced Refractory Solid Tumors. Journal of Hematology & Oncology, 9, 105. [Google Scholar] [CrossRef] [PubMed]
[26] Dobbin, S., Cameron, A.C., Petrie, M.C., et al. (2018) Toxicity of Cancer Therapy: What the Cardiologist Needs to Know about Angiogenesis Inhibitors. Heart (British Cardiac Society), 104, 1995-2002. [Google Scholar] [CrossRef] [PubMed]
[27] Touyz, R.M., Lang, N.N., Herrmann, J., et al. (2017) Recent Advances in Hypertension and Cardiovascular Toxicities with Vascular Endothelial Growth Factor Inhibition. Hyperten-sion, 70, 220-226. [Google Scholar] [CrossRef] 
[28] Si, X., Zhang, L., Wang, H., et al. (2019) Man-agement of Anlotinib-Related Adverse Events in Patients with Advanced Non-Small Cell Lung Cancer: Experiences in ALTER-0303: Adverse Event Management of Anlotinib. Thoracic Cancer, 10, 551-556. [Google Scholar] [CrossRef] [PubMed]
[29] Lr, A., Rd, B., Tp, A., et al. (2019) Management of Adverse Events Associated with Tyrosine Kinase Inhibitors: Improvingoutcomes for Patients with Hepatocellular Carcinoma. Cancer Treatment Reviews, 77, 20-28. [Google Scholar] [CrossRef] [PubMed]
[30] Miura, S.I., Fujino, M., Matsuo, Y., et al. (2005) Nifedi-pine-Induced Vascular Endothelial Growth Factor Secretion from Coronary Smooth Muscle Cells Promotes Endothelial Tube Formation via the Kinase Insert Domain-Containing Receptor/Fetal Liver Kinase-1/NO Pathway. Hypertension Re-search, 28, 147-153. [Google Scholar] [CrossRef] [PubMed]
[31] Sastre, J., Argilés, G., Benavides, M., et al. (2014) Clinical Manage-ment of Regorafenib in the Treatment of Patients with Advanced Colorectal Cancer. Clinical & Translational Oncology, 16, 942-953. [Google Scholar] [CrossRef] [PubMed]
[32] Mitchell, J., Khoukaz, T., Mcneal, D., et al. (2014) Adverse Event Management Strategies: Optimizing Treatment with Regorafenib in Patients with Metastatic Colorectal Cancer. Clinical Journal of Oncology Nursing, 18, E19-E25. [Google Scholar] [CrossRef] 
[33] Srinivas, S., Stein, D., Teltsch, D.Y., et al. (2017) Real-World Chart Review Study of Adverse Events Management in Patients Taking Tyrosine Kinase Inhibitors to Treat Metastatic Renal Cell Carcinoma. Journal of Oncology Pharmacy Practice, 24, 574-583. [Google Scholar] [CrossRef] [PubMed]
[34] Berger, A.M., Mooney, K., Alvarez-Perez, A., et al. (2015) Can-cer-Related Fatigue, Version 2. Journal of the National Comprehensive Cancer Network, 13, 1012-1039. [Google Scholar] [CrossRef] [PubMed]
[35] Bower, J.E., Ba, K.K., Berger, A., et al. (2014) Screening, Assess-ment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncol-ogy, 32, 1840-1850. [Google Scholar] [CrossRef] 
[36] Kim, S.Y., Kim, S.M., Chang, H., et al. (2019) Safety of Tyrosine Kinase Inhibitors in Patients with Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea. Frontiers in Endocrinology, 10, 384. [Google Scholar] [CrossRef] [PubMed]
[37] Ding, F.X., et al. (2019) Risk of Hand-Foot Skin Reaction Associ-ated with VEGFR-TKIs: A Meta-Analysis of 57 Randomized Controlled Trials Involving 24,956 Patients. Journal of the American Academy of Dermatology, 83, 788-796. [Google Scholar] [CrossRef] [PubMed]
[38] Li, J. and Gu, J. (2017) Hand-Foot Skin Reaction with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Can-cer Patients: A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology, 119, 50-58. [Google Scholar] [CrossRef] [PubMed]
[39] Schmidinger, M. (2013) Understanding and Managing Toxic-ities of Vascular Endothelial Growth Factor (VEGF) Inhibitors. EJC Supplements, 11, 172-191. [Google Scholar] [CrossRef] [PubMed]
[40] Wang, D., Lehman, R.E., Donner, D.B., et al. (2002) Expression and Endocytosis of VEGF and Its Receptors in Human Colonic Vascular Endothelial Cells. American Journal of Physi-ology Gastrointestinal & Liver Physiology, 282, G1088. [Google Scholar] [CrossRef] [PubMed]
[41] Fan, L. and Iseki, S. (1998) Immunohistochemical Localization of Vascular Endothelial Growth Factor in the Endocrine Glands of the Rat. Archives of Histology & Cytology, 61, 17. [Google Scholar] [CrossRef] [PubMed]
[42] Placidi, E., Marciani, L., Hoad, C.L., et al. (2012) The Effects of Loperamide, or Loperamide plus Simethicone, on the Distribution of Gut Water as Assessed by MRI in a Mannitol Model of Secretory Diarrhoea. Alimentary Pharmacology & Therapeutics, 36, 64-73. [Google Scholar] [CrossRef] [PubMed]
[43] Abbas, A., Mirza, M.M., Ganti, A.K., et al. (2015) Renal Toxicities of Targeted Therapies. Targeted Oncology, 10, 487-499. [Google Scholar] [CrossRef] [PubMed]
[44] Estrada, C.C., Maldonado, A. and Mallipattu, S.K. (2019) Thera-peutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. Journal of the American Society of Nephrology, 30, 187-200. [Google Scholar] [CrossRef] 
[45] Shao, F., Zhang, H., Yang, X., et al. (2020) Adverse Events and Management of Apatinib in Patients with Advanced or Metastatic Cancers: A Review. Neoplasma, 67, 715-723. [Google Scholar] [CrossRef] 

为你推荐